Barclays PLC Purchases 8,422 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Barclays PLC lifted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 4.5% during the 4th quarter, HoldingsChannel reports. The firm owned 196,051 shares of the company’s stock after acquiring an additional 8,422 shares during the period. Barclays PLC’s holdings in Syndax Pharmaceuticals were worth $2,592,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SNDX. Assenagon Asset Management S.A. boosted its holdings in shares of Syndax Pharmaceuticals by 343.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after buying an additional 1,598,428 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Syndax Pharmaceuticals during the 4th quarter valued at about $9,002,000. Trexquant Investment LP boosted its stake in Syndax Pharmaceuticals by 1,309.7% during the fourth quarter. Trexquant Investment LP now owns 471,292 shares of the company’s stock worth $6,230,000 after acquiring an additional 437,859 shares in the last quarter. Franklin Resources Inc. grew its holdings in Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock worth $34,948,000 after purchasing an additional 208,043 shares during the period. Finally, abrdn plc bought a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at approximately $1,313,000.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $14.15 on Thursday. Syndax Pharmaceuticals, Inc. has a one year low of $9.66 and a one year high of $25.07. The business’s fifty day moving average is $12.96 and its 200 day moving average is $14.79. The stock has a market capitalization of $1.22 billion, a PE ratio of -3.90 and a beta of 1.28.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $86.32 million. As a group, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Ratings Changes

SNDX has been the topic of a number of analyst reports. Citigroup dropped their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, March 20th. Finally, HC Wainwright restated a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares of the company’s stock, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the sale, the insider now owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).